FDA announcements and internal leaks has generated a storm of controversy about drug development and vaccines
The U.S. Food and Drug Administration is often described as the most influential scientific regulator in the world. Its decisions shape global drug development , investment, and patient access. But in recent weeks, the agency has undergone one of the most tumultuous periods in its modern history.
A cascade of announcements and internal leaks has generated a storm of controversy, culminating in the abrupt retirement offrom the agency’s top vaccine regulator Dr. Vinay Prasad, a new proposed approval pathway for bespoke therapies, and a rare, forcefulfrom former FDA commissioners. Together, these events have sparked vigorous debate about how the FDA should balance speed, safety, scientific rigor, and public trust.last week that the FDA would shift from decades of precedent requiring two adequate and well-controlled trials to a new expectation of only one pivotal trial for most new drugs. In interviews, Makary called the change “more practical,” arguing that, “You can achieve the same statistical power with one trial as you would with two,” as—the FDA has relied on dual independent replication as the cornerstone of evidentiary reliability. The two-trial standard became the regulatory gold standard, especially for drugs treating large or heterogeneous disease populations. Although the FDA has long possessed statutory flexibility to approve a drug based on one trial plus confirmatory evidence, making one trial the default represents a profound philosophical shift.described the change in striking terms, “The biggest jailbreak in biotech history…Makary just dropped a regulatory acceleration warhead in the middle of every portfolio model in the industry.”The economic implications are significant. Eliminating a second Phase III trial can shorten timelines by years and cut hundreds of millions from development costs., “Indications with large, heterogeneous populations and multiple existing therapies have historically required stronger evidence…We are concerned about the long-term risks that a lower approval threshold may introduce,” according toAbout the same time, a leaked internal memo from Dr. Vinay Prasad, head of the FDA’s vaccine division, ignited an entirely different controversy.that “at least 10 children” died “after and because of” COVID-19 vaccination, a statement without precedent in FDA messaging. Prasad claimed the analysis came from reviewing 96 pediatric death reports submitted to VAERS between 2021 and 2024. He argued that the true number “is certainly higher” and stated, “For the first time, the US FDA will acknowledge that COVID-19 vaccines have killed American children.”also outlined a tightening of vaccine-approval standards. It signaled that most new vaccines will require full randomized controlled trials rather than the long-standing reliance on immunogenicity surrogates that have supported approvals for seasonal influenza, pneumococcal, and other routine vaccines. In addition, the memo proposed ending the use of antibody-titer bridging to expand indications, calling instead for pre-market clinical-endpoint data in relevant populations. It further committed the agency to revisiting the entire framework for annual flu-vaccine updates, describing current practices as methodologically weak and announced increased scrutiny of simultaneous vaccine administration, noting that existing studies are too small to draw reliable safety conclusions. Taken together, these changes would amount to a wholesale reengineering of vaccine regulation and signal a striking move toward higher evidentiary thresholds. In essence, while Makary’s reforms would lower evidence requirements for therapeutics, Prasad proposed to raise them significantly for vaccines.. The memo was criticized as presented with no underlying data using a passive, unverified reporting system not designed to establish causality. Also, these large policy shifts were being proposed through an internal memo circulated without advisory-committee review or public evidence.New England Journal of Medicine article proposing a new “Plausible Mechanism Pathway.” The pathway would allow certain bespoke genetic therapies including single-patient gene editing approaches to obtain FDA marketing authorization based on mechanistic rationale, natural-history data, and early clinical improvement. The article cites the case of “Baby K.J.,” who received an adenine base-editing therapy under single-patient expanded access after one week of FDA review. The case illustrated how individualized treatments might be used to generate evidence toward future approvals. Key criteria in this proposed framework include a clearly identified molecular defect that is directly responsible for the patient’s disease; a therapy designed to act precisely on that defect rather than on downstream or nonspecific pathways; and a well-characterized natural history that allows regulators to distinguish true treatment effects from the expected clinical course. The framework also requires evidence that the therapy successfully engages or edits its biological target, supported by preclinical models or, when feasible, clinical confirmation. Finally, the FDA expects observable clinical improvement that aligns with disease biology, whether sustained remission in relapsing conditions or measurable, durable gains in progressive diseases, ensuring that mechanistic plausibility is matched by real-world therapeutic benefit., The NEJM article “is not a formal guidance document… significant questions remain regarding how FDA might operationalize and implement the proposed pathway.”Signed by 11 former FDA commissioners and senior leaders, the article warned that Prasad’s memo and related proposals “undermine the public interest” and break sharply with the FDA’s tradition of scientific integrity. Their concerns were broad. They warned that rejecting immunobridging — a tool the FDA has long relied on to update vaccines for rapidly evolving pathogens — would effectively cripple the nation’s ability to keep pace with viruses like influenza and SARS-CoV-2. Mandating randomized controlled trials for every indication, they argued, could delay or even prevent timely access to essential immunizations, particularly for vulnerable populations. They also cautioned that asserting vaccine-related deaths without transparent methods or publicly vetted evidence risked collapsing already fragile public confidence in immunization programs. And perhaps most troubling, the memo’s directive that staff who disagreed with the new framework should “submit your resignation letters” signaled an erosion of scientific norms that depend on open debate, internal dissent, and rigorous, transparent review. The authors wrote, “These measures… pose a serious threat to evidence-based public-health policy…The memo’s logic misrepresents both the science and the regulatory record.” Such a unified, direct, and public rebuke from former commissioners is virtually unheard of. Their intervention signaled not just disagreement, but a belief that the agency’s current direction represented a systemic and national-security concern.On December 2, days after Prasad’s memo, Richard Pazdur, an FDA veteran and director of CDER, abruptly submitted his resignation.reported that Pazdur had only accepted the CDER role weeks earlier after assurances of autonomy. But he reportedly clashed with Makary over both the one-trial policy and the National Priority Voucher program, an initiative that allows the Commissioner’s office to fast-track selected products., Pazdur’s departure leaves only three senior leaders remaining from the FDA’s leadership team a year ago. Nearly 90% of senior leaders have exited during the past 12 months., who said:, “This constant turmoil is undermining America’s leadership in biotechnology…We are at a tipping point. It is time to right this ship.”. Instead of a first dose within 24 hours of birth — as the CDC has advised for more than 30 years — the panel voted to recommend delaying it until a child is 2 months old for children born to mothers who test negative for the virus.how pulling back the long-standing recommendation for the hepatitis B birth dose, has alarmed pediatricians and public-health experts who view the universal birth-dose policy as essential protection against a virus often transmitted unknowingly from mother to child. Medical experts and organizations including theopposed such a change, saying it will leave young children at risk of an infection that can cause lifelong illness. They point to decades of research confirming the vaccine's safety and effectiveness. Critics warn that reversing this recommendation would reintroduce preventable infections and undermine decades of progress in eliminating perinatal hepatitis B. The debate highlights a broader pattern: as federal advisory bodies revisit foundational vaccine practices against a backdrop of heightened political scrutiny, even well-established immunization standards are now being questioned, adding another layer of uncertainty to an already turbulent regulatory environment.The FDA is undergoing profound changes. The agency is simultaneously lowering thresholds for therapeutics while raising them for vaccines, creating divergent standards that many experts find difficult to reconcile. Public disputes among senior leaders spill into the open. Together, these developments signal an agency at a crossroads, struggling to redefine its identity amid rapid scientific advances, political pressure, and eroding internal cohesion. Some argue this is a long-overdue modernization. Others believe the agency is veering toward incoherence without a unifying regulatory philosophy. The FDA seems to be entering a moment of existential debate about its role, its methods, and its future. Stability, transparency, and scientific clarity will be essential to restore confidence.
Makary Prasad Drug Development Clinical Trials Vaccines Health Policy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Recalls 2 Glucose Monitors That Can Lead to 'Injury or Death'Ariana Brockington is a trending news reporter at TODAY digital. She is based in Los Angeles.
Read more »
Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warnsThe U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths.
Read more »
FDA warns against Abbott's glucose monitor sensors after deathsThe U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths. Abbott Diabetes Care said about three million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors were affected.
Read more »
Bitcoin (BTC) Price News: Back to $90K as Bounce Fails for NowSofter than expected private inflation data did spark some hope that the Friday decline could reverse.
Read more »
Research Roundup: Holiday Parties, CEO Announcements, Low-Trust Negotiations, and MoreNew insights from academia, consultancies, and other sources to help your company make informed decisions.
Read more »
FDA instability, alarm over agency’s direction escalate after top regulator exitsAs leadership churn continues, FDA’s unpredictability rattles companies relying on stable regulation.
Read more »